Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-01
2011-11-01
Woodward, Cherie M (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021300, C424S146100, C530S350000
Reexamination Certificate
active
08048847
ABSTRACT:
This invention relates to the use of the IL-2 common gamma (cγc) and related molecules for the modulation of signal activities controlled by NIK, and some new such molecules.
REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5510259 (1996-04-01), Sugamura et al.
patent: 5844073 (1998-12-01), Rothe et al.
patent: 6610658 (2003-08-01), Findeis et al.
patent: 7070972 (2006-07-01), O'Shea et al.
patent: 0578932 (1994-01-01), None
patent: 07-133298 (1995-05-01), None
Malinin et al., Nature. Feb. 6, 1997;385(6616):540-4, Abstract Only.
Song et al., PNAS USA Sep. 2, 1997;94(18):9792-6, Abstract Only.
Dejardin et al., Immunity. Oct. 2002;17(4):525-35, Abstract Only.
Ramakrishnan et al., Immunity. Oct. 2004;21(4):477-89, Abstract Only.
O'Connell et al., (J Mol Evol., 2005; 61:608-619).
Benjamin et al., “A Plasticity Window for Blood Vessel Remodelling is Defined by Pericyte Coverage of the Preformed Endothelial Network and is Regulated by PDGF-B and VEGF,” 1998, Development 125:1591-1598.
Bork et al., “Go Hunting in Sequence Databases but Watch Out for the Traps,” Trends in Genetics. 1996; 12:425-427.
Bork., “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research. 2000; 10:398-400.
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science. 1990; 247:1306-1310.
Brenner, S. E., “Errors in Genome Annotation,” Trends in Genetics. 1999; 15:132-133.
Dejardin et al., “The Lymphotoxin-beta Receptor Different Patterns of Gene Expression Via Two NF-kappaB Pathways,”Immunity. Oct. 2002;17(4):525-35, Abstract Only.
Doerks et al., “Protein Annotation: Detective Work for Function Prediction,” Trends in Genetics. 1998; 14:248-250.
Malinin et al., “MAP3K-related Kinase Involved in NF-kappaB Induction by TNF, CD95 and IL-1,” Nature. Feb. 6, 1997;385(6616):540-4, Abstract Only.
Massague, J., “The TGF-β Family of Growth and Differentiation Factors,” Cell. 1987; 49:437-8.
O'Connell et al., “Gamma Chain Receptor Interleukins: Evidence for Positive Selection Driving the Evolution of Cell-to-Cell-Communications in the Mammalian Immune System,” J Mol Evol., 2005; 61 :608-619.
Pilbeam et al., “Comparison of the Effects of Various Lengths of Synthetic human Parathyroid Hormone-Related Peptide (hPTHrp) of Malignancy on Bone Resorption and Formation in Organ Culture,” Bone. 1993; 14:717-720.
Ramakrishnan et al., “Receptor-Specific Signaling for Both the Alternative and the Canonical NF-kappaB Activation Pathways by NF-kappaB-inducing Kinase,” Immunity. Oct. 2004;21 (4):477-89, Abstract Only.
Skolnick et al., “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era,” Trends in Biotech. 2000; 18:34-39.
Smith et al., “The Challenges of Genome Sequence Annotation or The Devil is in Details,” Nature Biotechnology. 1997; 15:1222-122b.
Song et al.,“Tumor Necrosis Factor (TNF)-Mediated Kinase Cascades: Bifurcation of Nuclear Factor-kappaB and C-jun N-Terminal Kinase (JNK/SAPK) Pathways at TNF Receptor-Associated Factor 2,” PNAS USA Sep. 2, 1997;94 (18):9792-6, Abstract Only.
Vukicevic et al., “Induction of Nephrogenic Mesenchyme by Osteogenic Protein 1 (Bone Morphogenetic Protein 7),” PNAS USA.1996; 93:9021-9026.
Wells, J. A. “Additivity of Mutational Effects in Proteins,” Biochemistry. 1990; 29:8509-8517.
Accession P31785, “RecName: Full=Cytokine receptor common subunit gamma; AltName: Full-Interleukin-2 receptor subunit gamma; Short=IL-2 receptor subunit gamma; Short-IL-2R subunit gamma; Short-IL-2RG; AltName: Full-p64; AltName: CD—antigen=CD132; Flags: Precursor”, pp. 1-9, May 26, 2001.
Adang, et al., Abstract Only, “The contribution of combinatorial chemistry to lead generation: an interim analysis”,Curr. Med. Chem., vol. 8(9), pp. 985-998, Jul. 2001.
Baldwin, Albert S. Jr., “The NF-κB and IκB Proteins: New Discoveries and Insights”,Annu. Rev. Immunol., vol. 14, pp. 649-683, 1996.
Fields, et al., Abstract Only, “A novel genetic system to detect protein-protein interactions”,Nature, vol. 340, pp. 245-246, 1989.
Ghosh, et al., Abstract Only, “NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses”,Annu. Rev. Immunol., vol. 16, pp. 225-260, 1998.
Karin, et al., Abstract Only, “Phosphorylation meets ubiquitination: the control of NF-[Kappa]B activity”,Annu. Rev. Immunol., vol. 18, pp. 621-663, 2000.
Leonard, et al., Abstract Only, “Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development”,Immunol. Rev., vol. 148, pp. 97-114, Dec. 1995.
Lin, et al., “The Proto-OncogeneCotKinase Participates in CD3/CD28 Induction of NF-kappaB Acting through the NF-kappaB-Inducing Kinase and IkappaB Kinases”,Immunity, vol. 10, pp. 271-280, Feb. 1999.
Malinin, et al., “MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1”,Nature, vol. 385, pp. 54-544, Feb. 1997.
Mercuric, et al., “Multiple signals converging on NF-kappaB”,Curr Opin. Cell Biol, vol. 11, pp. 226-232, 1999.
Miyawaki, et al., Abstract Only, “A new mutation, aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice”,Eur. J Immunol, vol. 24, pp. 429-434, 1994.
Noguchi, et al., Abstract Only, “Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans”,Cell, vol. 73, pp. 147-157, 1993.
Regnier, et al., “Identification and Characterization of an IkappaB Kinase”,Cell, vol. 90, pp. 373-383, Jul. 1997.
Rothe, et al., Abstract Only, “A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor”,Cell, vol. 78, pp. 681-692, Aug. 1994.
Senftleben, et al., “Activation by IKKalpha of a Second, Evolutionary Conserved, NF-kappaB Signaling Pathway”,Science, vol. 293, pp. 1495-1499, Aug. 2001.
Shinkura, et al., Abstract Only, “Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase”,Nat. Genet., vol. 22, pp. 74-77, May 1999.
Smith, G.P., Abstract Only, “Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface”,Science, vol. 228, pp. 1315-1317, Jun. 1985.
Takeshita, at al., “Cloning of the gamma chain of the human IL-2 receptor”,Science, vol. 257, pp. 379-382, Jul. 1992.
Xiao, et al., “NF-kappaB-Inducing Kinase Regulates the Processing of NF-kappaB2 p100”,Mol Cell, vol. 7, pp. 401-409, Feb. 2001.
Yin, et al., “Defective Lymphotoxin-beta Receptor-Induced NF-kappaB Transcriptional Activity in NIK-Deficient Mice”,Science, vol. 291, pp. 2162-2165, Mar. 2001.
“Sequence 4 from patent US 5510259,” GenBank: AAB11694.1 (1996).
“Sequence 7 from patent US 5510259,” GenBank: AAB11695.1 (1996).
Akiba et al., “CD27, a Member of the Tumor Necrosis Factor Receptor Superfamily, Activates NF-kB and Stress-activated Protein Kinase/c-Jun N-terminal Kinase via TRAF2, TRAF5, and NF-kB-inducing Kinase*”, The Journal of Biological Chemistry, May 22, 1998, vol. 273, No. 21, pp. 13353-13358.
Canicio et al., “Nuclear Factor kB-inducing Kinase and IkB Kinase—a Signal Skeletal Muscle Cell Differentiation”, The Journal of Biological Chemistry, Jun. 8, 2001, vol. 276, No. 23, pp. 20228-20233.
Darnay et al., “Activation of NF-kB by RANK Requires Tumor Necrosis Factor Receptor-associated Factor (TRAF) 6 and NF-kB-inducing Kinase”, The Journal of Biological Chemistry, Mar. 19, 1999, vol. 274, No. 12, pp. 7724
Ramakrishnan Parameswaran
Shmushkovich Taisia
Wallach David
Browdy and Neimark PLLC
Woodward Cherie M
Yeda Research and Development Co. Ltd.
LandOfFree
Derivatives of the IL-2 receptor gamma chain, their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of the IL-2 receptor gamma chain, their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of the IL-2 receptor gamma chain, their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4256993